Plain-English translation of NCT06384560 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach to treating pancreatic cancer that hasn't spread. Instead of going straight to surgery, patients receive three treatments together first: chemotherapy (mFOLFIRINOX), an immunotherapy drug called , and targeted radiation therapy. After these treatments shrink or stabilize the cancer, patients then have surgery to remove it, followed by more chemotherapy and immunotherapy.
Pancreatic cancer is very aggressive and patients often don't survive long, even after surgery. Researchers believe that giving strong treatments before surgery—rather than after—might kill more cancer cells and give patients a better chance of living longer.
You likely qualify if…
You likely don't qualify if…
You would start treatment with four cycles of chemotherapy given every two weeks, combined with immunotherapy every six weeks. After these four cycles, scans check how well the cancer is responding. If the cancer has shrunk or stayed stable, you receive focused radiation therapy (5 sessions), then four more cycles of chemotherapy and immunotherapy. About 3–6 weeks after finishing all treatments, you have surgery to remove the cancer. After surgery, you complete four more cycles of chemotherapy and immunotherapy. The entire process typically takes several months.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Netherlands